Phase 3 N=14 Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
Pediatric Crohn's Disease
Primary: Percent of Patients Who Achieved PCDAI Response — 78.6; 100.0; 100.0; 92.9 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Crohn Disease Exclusion Diet After Single Medication De-escalation
Crohn Disease
Primary: Sustained Relapse-free Remission — 6; 5 Participants
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
Phase 3 N=192 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26 — 28.4; 38.7 percent of participants…
Phase 3 N=108 Safety Study of Entocort for Children With Crohn's Disease
Crohn's Disease
Primary: Adverse Event — 79 Patients
Phase 2 N=15 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants
Phase 2 N=12 The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease
Crohn's Disease
Primary: Number of Patients Reporting Side Effects — 2; 2; 0; 2 participants — p=1.0
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
N/A N=15 The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
Phase 2 N=89 Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis · Crohn's Disease
Primary: AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14 — 1933.5076; 3231.1001; 2344.4204; 3091.7957 h*ng/mL
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Phase 4 N=428 Predicting Response to Standardized Pediatric Colitis Therapy
Ulcerative Colitis
Primary: Number of Participants With Corticosteroid Free Remission (SFR) — 80; 70 Participants
Phase 3 N=50 Safety and Maintenance Study of Entocort for Children With Crohn's Disease
Crohn's Disease
Primary: Adverse Event — 37 Subjects
N/A N=138 Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial
Crohn Disease
Primary: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months — 0.15; 0.23 Z-score — p=0.38
Phase 3 N=306 Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Pediatric Crohn's Disease
Primary: Percent of Participants Experiencing Treatment Failure — 25.64; 34.04 percentage of participants — p=0.08
Phase 3 N=60 A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
Ulcerative Colitis
Primary: The Number of Participants With Clinical Response at Week 8 — 44 Participants
Phase 2 N=20 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
Phase 2 N=262 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393
N/A N=45 Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Diseases
Primary: Pre-treatment Serum Level of Endogenous Anti-TNF in Relation to Primary Clinical Response or Non-response — NA endogenous anti-TNF serum level (µg/mL)
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 3 N=53 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8 — 10; 17 Participants — p=0.039
Phase 3 N=101 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period — 43.3; 59.6…
Phase 2 N=59 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis · Crohn's Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 100; 83.3; 100; 100 percentage of participants
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Phase 3 N=112 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Crohn's Disease
Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526
Phase 3 N=59 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Adverse Events (AEs) — 55; 15 Participants
Phase 3 N=396 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Crohn's Disease
Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001
N/A N=78 A Trial of Yoga in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Pediatric Quality of Life Inventory — 2.14; 1.5; 2.8 score on a scale
Phase 3 N=21 Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
Pediatric Ulcerative Colitis
Primary: Percent of Patients Who Achieved CAI Remission — 60.0; 80.0; 80.0; 77.8 percentage of participants